Migraines with and without aura and their response to preventive therapy with topiramate
U Reuter,
MS Del Rio, H-C Diener, G Allais, B Davies,
A Gendolla, J Pfeil, S Schwalen, B Schäuble, J Van Oene,
Corresponding Author
U Reuter
Charité Universitätsmedizin, Berlin,
Dr Uwe Reuter, Charité Universitätsmedizin Berlin, Department of Neurology, 10119 Berlin, Germany. Tel. + 49-304-5056-0274, fax + 49-304-5056-0932, e-mail [email protected]Search for more papers by this authorB Davies
University Hospital of North Staffordshire, Stoke-on-Trent, UK
Search for more papers by this authorU Reuter,
MS Del Rio, H-C Diener, G Allais, B Davies,
A Gendolla, J Pfeil, S Schwalen, B Schäuble, J Van Oene,
Corresponding Author
U Reuter
Charité Universitätsmedizin, Berlin,
Dr Uwe Reuter, Charité Universitätsmedizin Berlin, Department of Neurology, 10119 Berlin, Germany. Tel. + 49-304-5056-0274, fax + 49-304-5056-0932, e-mail [email protected]Search for more papers by this authorB Davies
University Hospital of North Staffordshire, Stoke-on-Trent, UK
Search for more papers by this authorAbstract
Data from the Prolonged Migraine Prevention (PROMPT) with Topiramate trial were evaluated post hoc to determine whether topiramate could prevent migraine auras, and whether its efficacy in preventing migraine headaches was similar in patients with (MA; n = 269) and without (MoA; n = 542) aura. Migraines and auras were recorded during prospective baseline, 6-month open-label (OL) topiramate and 6-month double-blind (DB), placebo-controlled phases. In the last 28 OL days, migraines without aura and migraine auras decreased by 43.1% and 54.1%, respectively, in MA patients. MoA patients experienced a 44.3% reduction in migraines. In the DB phase, increases in migraines with placebo vs. topiramate were similar to the full study, but were generally not statistically significant, probably due to lack of power in the subgroup analysis. Similarly, there were no statistically significant changes in number of auras between groups. Thus, topiramate appears to reduce migraine auras in parallel with headache reductions, which are similar in patients with and without aura.
References
- 1 Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–9.
- 2
Boes CJ,
Capobianco DJ,
Cutrer M,
Dodick D,
Eross EJ,
Swanson JW.
Headache and other craniofacial pain. In: W Bradley,
RB Daroff,
GM Fenichel,
J Jankovic, eds.
Neurology in clinical practice, 5th
edn.
Philadelphia: Butterworth
2008: 2011–62.
10.1016/B978-0-7506-7525-3.50111-4 Google Scholar
- 3 Kurth T, Schurks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 2008; 337: a636.
- 4 Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia 2004; 24: 728–34.
- 5 Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885–94.
- 6 Mattsson P, Lundberg PO. Characteristics and prevalence of transient visual disturbances indicative of migraine visual aura. Cephalalgia 1999; 19: 479–84.
- 7 Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671–7.
- 8 Mariani C, Farina E, Scarlato G. Intravenous verapamil in acute migraine with prolonged aura. Eur J Med 1992; 1: 319.
- 9 Rozen TD. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology 2000; 55: 732–3.
- 10 Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55: 139–41.
- 11 Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490–5.
- 12 Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965–73.
- 13 Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943–50.
- 14 Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007; 6: 1054–62.
- 15 Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12: 81–4.
- 16 Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491–512.
- 17 Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D'Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008; 70: 548–55.
- 18 Ochoa JG, Riche W. Antiepileptic drugs: an overview. [WWW document]. URL http://emedicine.medscape.com/article/1187334-overview (Last accessed March 2009)
- 19 Hadjikhani N, Sanchez Del RM, Wu O, Schwartz D, Bakker D, Fischl B et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001; 98: 4687–92.
- 20 Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 2005; 16: 1383–7.
- 21 Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006; 59: 652–61.
- 22 Wolthausen J, Sternberg S, Gerloff C, May A. Are cortical spreading depression and headache in migraine causally linked? Cephalalgia 2009; 29: 244–9.
- 23 Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol 1994; 34: 30–5.
- 24 Smith MI, Read SJ, Chan WN, Thompson M, Hunter AJ, Upton N et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000; 20: 546–53.
- 25 Wiedemann M, De Lima VM, Hanke W. Effects of antimigraine drugs on retinal spreading depression. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 552–6.
- 26 Read SJ, Hirst WD, Upton N, Parsons AA. Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res 2001; 891: 69–77.
- 27 Rothrock JF. Successful treatment of persistent migraine aura with divalproex sodium. Neurology 1997; 48: 261–2.
- 28 Fujita M, Fujiwara J, Maki T, Shigeta M, Shibasaki K, Takahashi N et al. The efficacy of sodium valproate and a MRA finding in confusional migraine. Brain Dev 2007; 29: 178–81.
- 29 D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64–6.
- 30 Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia 1999; 19: 58–63.
- 31 Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76: 1730–2.
- 32 Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008; 28: 585–97.
